XTRA:EUZ

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Eckert & Ziegler Strahlen- und Medizintechnik

Executive Summary

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide. More Details


Snowflake Analysis

Flawless balance sheet average dividend payer.

Share Price & News

How has Eckert & Ziegler Strahlen- und Medizintechnik's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EUZ has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-6.5%

EUZ

-1.1%

DE Medical Equipment

-5.2%

DE Market


1 Year Return

1.1%

EUZ

23.6%

DE Medical Equipment

-3.8%

DE Market

Return vs Industry: EUZ underperformed the German Medical Equipment industry which returned 24.4% over the past year.

Return vs Market: EUZ matched the German Market which returned 0.2% over the past year.


Shareholder returns

EUZIndustryMarket
7 Day-6.5%-1.1%-5.2%
30 Day-4.1%5.7%-2.2%
90 Day10.5%-1.6%-4.2%
1 Year2.3%1.1%25.3%23.6%-0.8%-3.8%
3 Year375.5%353.8%178.0%171.4%-3.7%-12.1%
5 Year836.8%750.6%314.5%297.0%16.7%0.1%

Price Volatility Vs. Market

How volatile is Eckert & Ziegler Strahlen- und Medizintechnik's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Eckert & Ziegler Strahlen- und Medizintechnik undervalued compared to its fair value and its price relative to the market?

38.99x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: EUZ (€41.04) is trading above our estimate of fair value (€34.98)

Significantly Below Fair Value: EUZ is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: EUZ is good value based on its PE Ratio (39x) compared to the DE Medical Equipment industry average (56.4x).

PE vs Market: EUZ is poor value based on its PE Ratio (39x) compared to the German market (22.3x).


Price to Earnings Growth Ratio

PEG Ratio: EUZ is poor value based on its PEG Ratio (2.9x)


Price to Book Ratio

PB vs Industry: EUZ is overvalued based on its PB Ratio (6x) compared to the DE Medical Equipment industry average (4.2x).


Next Steps

Future Growth

How is Eckert & Ziegler Strahlen- und Medizintechnik forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

13.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EUZ's forecast earnings growth (13.6% per year) is above the savings rate (0.2%).

Earnings vs Market: EUZ's earnings (13.6% per year) are forecast to grow slower than the German market (26.2% per year).

High Growth Earnings: EUZ's earnings are forecast to grow, but not significantly.

Revenue vs Market: EUZ's revenue (9% per year) is forecast to grow faster than the German market (6% per year).

High Growth Revenue: EUZ's revenue (9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EUZ's Return on Equity is forecast to be low in 3 years time (15.5%).


Next Steps

Past Performance

How has Eckert & Ziegler Strahlen- und Medizintechnik performed over the past 5 years?

18.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EUZ has high quality earnings.

Growing Profit Margin: EUZ's current net profit margins (12.5%) are higher than last year (11.7%).


Past Earnings Growth Analysis

Earnings Trend: EUZ's earnings have grown by 18.3% per year over the past 5 years.

Accelerating Growth: EUZ's earnings growth over the past year (4.5%) is below its 5-year average (18.3% per year).

Earnings vs Industry: EUZ earnings growth over the past year (4.5%) underperformed the Medical Equipment industry 14.8%.


Return on Equity

High ROE: EUZ's Return on Equity (15.4%) is considered low.


Next Steps

Financial Health

How is Eckert & Ziegler Strahlen- und Medizintechnik's financial position?


Financial Position Analysis

Short Term Liabilities: EUZ's short term assets (€138.2M) exceed its short term liabilities (€38.1M).

Long Term Liabilities: EUZ's short term assets (€138.2M) exceed its long term liabilities (€87.7M).


Debt to Equity History and Analysis

Debt Level: EUZ's debt to equity ratio (0.01%) is considered satisfactory.

Reducing Debt: EUZ's debt to equity ratio has reduced from 17.3% to 0.01% over the past 5 years.

Debt Coverage: EUZ's debt is well covered by operating cash flow (165512.5%).

Interest Coverage: EUZ's interest payments on its debt are well covered by EBIT (42.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Eckert & Ziegler Strahlen- und Medizintechnik current dividend yield, its reliability and sustainability?

1.04%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: EUZ's dividend (1.04%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.25%).

High Dividend: EUZ's dividend (1.04%) is low compared to the top 25% of dividend payers in the German market (3.77%).


Stability and Growth of Payments

Stable Dividend: EUZ's dividends per share have been stable in the past 10 years.

Growing Dividend: EUZ's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (40.4%), EUZ's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: EUZ's dividends in 3 years are forecast to be well covered by earnings (33.3% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Andreas Eckert (60 yo)

no data

Tenure

€976,521

Compensation

Dr. Andreas Eckert, PhD, is the Founder and Managing Partner of ELSA Eckert Life Science Accelerator GmbH. Dr. Exkert is the Founder of Eckert & Ziegler Strahlen & Medizintechnik AG and serves as its Chief ...


CEO Compensation Analysis

Compensation vs Market: Andreas's total compensation ($USD1.15M) is about average for companies of similar size in the German market ($USD1.31M).

Compensation vs Earnings: Andreas's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Andreas Eckert
Chairman of Executive Board & CEOno data€976.52k0.21%
€ 1.8m
Harald Hasselmann
Head of Radiation Therapy Segment & Member of the Executive Board3.75yrs€365.95kno data
Lutz Helmke
Member of Executive Board2.08yrs€452.03kno data
Gunnar Mann
Head of Intragroup Services8.75yrsno datano data
Franklin Yeager
President of Eckert & Ziegler Isotope Products Inc.no datano datano data
Joseph Hathcock
Vice President of Eckert & Ziegler Isotope Products Incno datano datano data
Ivan Simmer
Managing Director of Eckert & Ziegler Cesio s.r.o.6.75yrsno datano data

5.3yrs

Average Tenure

56yo

Average Age

Experienced Management: EUZ's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Frank Perschmann
Member of Supervisory Board1.42yrs€9.00kno data
Wolfgang Maennig
Chairman of Supervisory Board7.42yrs€40.00kno data
Edgar Löffler
Member of Supervisory Board1.75yrs€17.00kno data
Helmut Grothe
Deputy Chairman of the Supervisory Board3.25yrs€29.00kno data
Albert Rupprecht
Member of Supervisory Board3.42yrs€16.00kno data
Jutta Ludwig
Member of Supervisory Board1.75yrs€17.00kno data

2.5yrs

Average Tenure

67yo

Average Age

Experienced Board: EUZ's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Eckert & Ziegler Strahlen- und Medizintechnik AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Ticker: EUZ
  • Exchange: XTRA
  • Founded: 1992
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €889.075m
  • Shares outstanding: 20.59m
  • Website: https://www.ezag.com

Number of Employees


Location

  • Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Robert-Rössle-Strasse 10
  • Berlin
  • Berlin
  • 13125
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EUZDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 1999
EUZXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURMay 1999
0NZYLSE (London Stock Exchange)YesOrdinary SharesGBEURMay 1999
EUZdBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURMay 1999
EUZETLX (Eurotlx)YesOrdinary SharesITEURMay 1999

Biography

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide. It operates through three segments: ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 22:04
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.